Copy‐number intratumor heterogeneity as high‐risk feature of stage <scp>II</scp> colon cancer <sup>†</sup>-Reference-Cited by-同舟云学术

Copy‐number intratumor heterogeneity as high‐risk feature of stage II colon cancer ^†

Published:2022-05-23 Issue:5 Volume:257 Page:575-578
ISSN:0022-3417
Container-title:The Journal of Pathology
language:en
Short-container-title:The Journal of Pathology

Author:

van den Bosch Tom¹²^ORCID,Miedema Daniël M¹²^ORCID,Vermeulen Louis¹²^ORCID

Affiliation:

1. Amsterdam UMC location University of Amsterdam, Cancer Center Amsterdam & Amsterdam Gastroenterology Endocrinology Metabolism, Center for Experimental and Molecular Medicine Amsterdam The Netherlands

2. Oncode Institute Amsterdam The Netherlands

Publisher

Wiley

Subject

Pathology and Forensic Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/path.5919

Reference12 articles.

1. Is adjuvant chemotherapy an option for stage II colon cancer?

2. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study

3. Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in stage II/III colorectal cancer

4. Copy‐number intratumor heterogeneity increases the risk of relapse in chemotherapy‐naive stage II colon cancer

5. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Construction and validation of a prognostic model for gastrointestinal stromal tumors based on copy number alterations and clinicopathological characteristics;Frontiers in Oncology;2022-12-21